Latest Breaking News On - Immunome inc - Page 8 : comparemela.com

Immunome (NASDAQ:IMNM) Shares Up 2.7%

Shares of Immunome, Inc. (NASDAQ:IMNM – Get Free Report) were up 2.7% on Tuesday . The company traded as high as $24.50 and last traded at $24.08. Approximately 59,193 shares traded hands during trading, a decline of 90% from the average daily volume of 570,022 shares. The stock had previously closed at $23.45. Analysts Set […]

Montreal
Quebec
Canada
Leerink-partnrs
Cerity-partners
Immunome-inc
Nasdaq
Td-asset-management-inc
Get-free-report
Management-inc
Montreal-can
Immunome-daily

Immunome Inc. (IMNM) Files Mixed Shelf

Immunome Inc. (IMNM) Files Mixed Shelf
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Nasdaq
Immunome-inc
Files-mixed
Categories-corporate-news

Immunome Inc. (IMNM) Announces Proposed $200M Share Offering

Immunome Inc. (IMNM) Announces Proposed $200M Share Offering
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Edgewood
New-york
United-states
Boston
Massachusetts
Wedbush-pacgrow
Equity-syndicate-department
Exchange-commission
Guggenheim-securities
Leerink-partners
Jp-morgan-securities
Broadridge-financial-solutions

Immunome Announces Proposed Public Offering of Common Stock

Immunome, Inc. , a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced its plans to commence an underwritten public offering,.

New-york
United-states
Edgewood
Boston
Massachusetts
Wedbush-pacgrow
Equity-syndicate-department
Exchange-commission
Immunome-inc
Syndicate-department
Leerink-partners
Guggenheim-securities

Immunome Announces Proposed Public Offering of Common Stock

Immunome, Inc. ("Immunome") , a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced its plans to commence an underwritten public offering, subject to market and other conditions,.

Boston
Massachusetts
United-states
New-york
Edgewood
Wedbush-pacgrow
Leerink-partners
Immunome-inc
Syndicate-department
Guggenheim-securities
Exchange-commission
Equity-syndicate-department